Open AccessPhase II study of induction chemotherapy followed by concurrent chemoradiotherapy with raltitrexed and cisplatin in locally advanced nasopharyngeal carcinoma
Author(s) -
Yuan Wu,
Xueyan Wei,
Zheng Yuan,
Hao Xu,
Yanping Li,
Ying Li,
Hu Liu,
Gia Hân,
Qian Yu,
Desheng Hu
Publication year - 2020
Publication title -
chinese journal of cancer research/chinese journal of cancer research
Language(s) - English
Resource type - Journals
eISSN - 1993-0631
pISSN - 1000-9604
DOI - 10.21147/j.issn.1000-9604.2020.05.11
Subject(s) - raltitrexed , medicine , mucositis , nasopharyngeal carcinoma , oncology , cisplatin , induction chemotherapy , regimen , chemoradiotherapy , chemotherapy , phases of clinical research , bone marrow suppression , radiation therapy , gastroenterology , surgery , thymidylate synthase , fluorouracil
For locally advanced nasopharyngeal carcinoma (LA-NPC) patients, high incidences of distant metastases and severe treatment related toxicities are the main obstacles needed to be overcome. Raltitrexed, a specific thymidylate synthase inhibitor with a convenient administration schedule, has an acceptable and manageable toxicity, and possesses radio-sensitizing properties. To investigate the efficacy and safety of raltitrexed and cisplatin induction chemotherapy and concurrent chemoradiotherapy (IC+CCRT) in patients with LA-NPC, a phase II clinical study was conducted.